

Correction

Correction: NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback regulation of PI3K/Akt signaling

Cuixiang Zhang^{1,2,*}, Tian Lan^{3,*}, Jincai Hou^{1,2}, Juan Li^{4,5}, Rende Fang^{4,5}, Zhicheng Yang⁴, Min Zhang⁶, Jianxun Liu^{1,2} and Bing Liu^{4,5}

¹Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 110300, China

²Beijing Key Laboratory of Pharmacology of Chinese Materia Medica, Beijing 110300, China

³Vascular Biology Research Institute, Guangdong Pharmaceutical University, Guangzhou 510006, China

⁴Department of Clinical pharmacy, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China

⁵Guangdong Key Laboratory of Pharmaceutical Bioactive Substances, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China

⁶Department of Health Statistics, School of Public Health, Guangdong Pharmaceutical University, Guangzhou 510006, China

* These authors have contributed equally to this work

Published:

Copyright: © 2021 Zhang et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 4C, the 4th image in the bottom row contains an accidental partial overlap of the 1st image in that row. In Figure 1B, the 2nd image in the first row contains an accidental partial overlap of the 1st image in that row. The corrected Figures 4C and 1B, produced using the original data, are shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2014; 5:4392–4405. <https://doi.org/10.18632/oncotarget.2025>




Figure 1: (B–C) IHC staining indicating that NOX4 expression is upregulated in human NSCLCs (clinical stage I–III) compared with adjacent normal lung tissues. Percentage of patients with high expression of NOX4 and low expression of NOX4 according to different clinical parameters as follows: tumor stage, tumor status, and lymph node status.




Figure 4: (A–C) Stably NOX4 overexpressing A549 and H460 cells were treated with 30 μ M of LY294002 or 10 μ M of Wortmannin and control solvent. The proliferation of cells was evaluated using MTT assay (A) and colony formation assay (B). The invasion of cells was evaluated using Matrigel transwell assay (C).